The U.S. Food and Drug Administration approved nerandomilast, marketed as Jascayd, for the treatment of idiopathic pulmonary fibrosis (IPF) [2, 3, 4].
This approval is significant because it provides the first new therapeutic option for a disease with limited treatments in more than 10 years [4]. For patients with IPF, a chronic condition characterized by lung scarring, the addition of a new approved drug marks a shift in the available standard of care.
The FDA announced the approval of Jascayd on Oct. 9, 2025 [2]. While some reports described it as the first treatment ever approved for patients with IPF [2], other records clarify that it is the first new therapy added to the clinical arsenal in over a decade [4].
Beyond the recently approved drug, other pharmaceutical efforts continue to advance. Rein Therapeutics recently reported that eight patients have enrolled in the Phase 2 RENEW study for LTI-03 [1, 5]. This trial is being conducted across multiple international sites to evaluate the efficacy of the candidate treatment.
The broader landscape for IPF research remains active. More than 80 companies currently maintain IPF programs [6], and there are more than 100 novel treatments currently in the development pipeline [6]. This surge in research reflects the urgent medical need for therapies that can slow the progression of lung fibrosis.
Dr. Roger Seheult of MedCram said these developments in a video recorded on April 9, 2026 [1]. He highlighted the evolving treatment landscape and the importance of these new clinical milestones for patient outcomes.
“Jascayd is the first new IPF therapy approved in over 10 years.”
The approval of Jascayd breaks a decade-long stagnation in IPF treatment, signaling a potential shift toward more diverse pharmacological interventions. With over 100 treatments in the pipeline and a growing number of companies entering the space, the medical community is moving toward a multi-drug approach to manage lung scarring, which has historically had very few effective options.
